The Molecular Pathogenesis of Osteosarcoma: A Review

Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemothe...

Full description

Bibliographic Details
Main Authors: Matthew L. Broadhead, Jonathan C. M. Clark, Damian E. Myers, Crispin R. Dass, Peter F. M. Choong
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Sarcoma
Online Access:http://dx.doi.org/10.1155/2011/959248
id doaj-c410c31dddd04a91b28d36d0f11464a4
record_format Article
spelling doaj-c410c31dddd04a91b28d36d0f11464a42020-11-24T21:32:02ZengHindawi LimitedSarcoma1357-714X1369-16432011-01-01201110.1155/2011/959248959248The Molecular Pathogenesis of Osteosarcoma: A ReviewMatthew L. Broadhead0Jonathan C. M. Clark1Damian E. Myers2Crispin R. Dass3Peter F. M. Choong4Department of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaDepartment of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaDepartment of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaSchool of Biomedical and Health Sciences, Victoria University, St. Albans, VIC 3021, AustraliaDepartment of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaOsteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational studies performed to date in search of novel, safer, and more targeted drugs for disease management.http://dx.doi.org/10.1155/2011/959248
collection DOAJ
language English
format Article
sources DOAJ
author Matthew L. Broadhead
Jonathan C. M. Clark
Damian E. Myers
Crispin R. Dass
Peter F. M. Choong
spellingShingle Matthew L. Broadhead
Jonathan C. M. Clark
Damian E. Myers
Crispin R. Dass
Peter F. M. Choong
The Molecular Pathogenesis of Osteosarcoma: A Review
Sarcoma
author_facet Matthew L. Broadhead
Jonathan C. M. Clark
Damian E. Myers
Crispin R. Dass
Peter F. M. Choong
author_sort Matthew L. Broadhead
title The Molecular Pathogenesis of Osteosarcoma: A Review
title_short The Molecular Pathogenesis of Osteosarcoma: A Review
title_full The Molecular Pathogenesis of Osteosarcoma: A Review
title_fullStr The Molecular Pathogenesis of Osteosarcoma: A Review
title_full_unstemmed The Molecular Pathogenesis of Osteosarcoma: A Review
title_sort molecular pathogenesis of osteosarcoma: a review
publisher Hindawi Limited
series Sarcoma
issn 1357-714X
1369-1643
publishDate 2011-01-01
description Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational studies performed to date in search of novel, safer, and more targeted drugs for disease management.
url http://dx.doi.org/10.1155/2011/959248
work_keys_str_mv AT matthewlbroadhead themolecularpathogenesisofosteosarcomaareview
AT jonathancmclark themolecularpathogenesisofosteosarcomaareview
AT damianemyers themolecularpathogenesisofosteosarcomaareview
AT crispinrdass themolecularpathogenesisofosteosarcomaareview
AT peterfmchoong themolecularpathogenesisofosteosarcomaareview
AT matthewlbroadhead molecularpathogenesisofosteosarcomaareview
AT jonathancmclark molecularpathogenesisofosteosarcomaareview
AT damianemyers molecularpathogenesisofosteosarcomaareview
AT crispinrdass molecularpathogenesisofosteosarcomaareview
AT peterfmchoong molecularpathogenesisofosteosarcomaareview
_version_ 1725958850797895680